RESULTS: The 26 (5.3%) patients who developed UUT-SPTs requiring surgical treatment after RC had predominantly invasive cancers (Ta ¼ 23.1%, Tis ¼ 11.5%, T1 ¼ 26.9%, T2 ¼ 19.2%, T3¼ 15.4%, T4 ¼ 3.9%) which were also predominantly high grade (G3¼ 88.5%, G2 ¼ 7.7 %, G1 ¼ 3.8). The mean time from RC to the development of SPT was 33.8 months. In a linear regression analysis that controlled for age, bladder pathologic tumor stage was significantly associated with decreased time to SPT (p¼ 0.030). Neoadjuvant CBT was given to 11.5 % of bladder UC patients prior to RC and 19.2% received adjuvant CBT after RC . Mean eGFR decreased from 69.3 prior to RC to 55.7 prior to UUT-SPT surgical treatment. UUT-SPTs were managed with nephroureterectomy (92.3%) or ureterectomy (7.7%), and ipsilateral lymphadenectomy (77%). Neoadjuvant CBT prior to UUT surgery was administered to 15.4% of patients. Mean eGFR further decreased after UUT-SPT surgery to 39.5, and 23.1% of patients received adjuvant CBT following UUT surgery. Patient were followed for a mean of 76.1 months and 38.5% of patients died of disease, 29.9% died of unknown/other causes, and 34.6% are alive with no evidence of disease.
INTRODUCTION AND OBJECTIVES: Urothelial carcinoma can occur in both the upper and lower urinary tract; however, the natural history of disease recurrence and outcomes in patients who ultimately require both radical cystectomy (RC) and radical nephroureterectomy (RNU) is poorly understood. We aim to define outcomes in these populations to better inform surveillance strategies following upper and lower tract resection for urothelial carcinoma.
METHODS: We retrospectively reviewed the medical records of patients who underwent both RC and RNU at the Mayo Clinic between 1995 and 2009. Patients who had undergone both RC and RNU were grouped by resection order. Time between resections and pathology data at the time of resection were determined, and Kaplan-Meier analysis was used to evaluate disease specific and overall survival.
RESULTS: Of 524 patients who underwent RNU at our institution, 100 (19%) patients also underwent RC. 49/100 (49%) underwent initial RC followed by RNU (RC->RNU), 24/100 (24%) underwent RNU followed by RC (RNU->RC), and 27/100 (27%) underwent simultaneous RC and RNU (RC+RNU). The median time between procedures was shorter for patients undergoing RNU->RC (14.6 months) compared to patients undergoing RC->RNU (42.6 months). Upper tract disease after RC (RC->RNU) was more likely to be Grade 3 (80.0%) and T3 or T4 (22.7%) than bladder cancer after RNU (RNU->RC; Grade 3: 58.3%; T3 or T4: 12.5%). Nevertheless, after the second surgery, there was no significant difference in median disease specific survival (DSS, Log-Rank, P¼0.28) or overall survival (OS, Log-Rank, P¼0.74) between groups RC->RNU (DSS: 83.7 months; OS: 110.1 months), RNU->RC (DSS: 74.3 months; OS: 149.9 months) and RC+RNU (DSS: 62.5 months; OS: 109.2 months).
CONCLUSIONS: Our data highlight the high frequency of synchronous and metachronous upper and lower tract urothelial carcinoma, with nearly 20% of patients undergoing RNU also requiring RC. Disease recurrence in the bladder after RNU occurred more rapidly than upper tract recurrence after RC. However, patients with upper tract recurrence after RC presented later and with higher grade and stage disease compared to patients presenting with lower tract recurrence after RNU. These data highlight the importance of long-term oncologic surveillance after both RC and RNU. . This has been described to be particularly useful in distinguishing between low-grade (LG) and highgrade (HG) bladder transitional cell carcinoma. However, little is known on its potential utility in upper tract urothelial carcinoma (UTUC). The aim of this study is to describe our initial experience with CLE for the evaluation of UTUC.
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METHODS: Between January and September 2016, 15 flexible ureteroscopies (f-URS) were performed at our center with CLE for UTUC. A semirigid and/or a flexible digital ureteroscope [Karl Storz, Tuttlingen, Germany] were used in all the patients. An initial inspection of the ureter and renal collecting system was performed in white light with a "no touch technique" (no wire) to macroscopically identify all potential suspicious lesions. CLE was then performed using the Cellvizioâ system (Mauna Kea Technologies, Paris, France) according to the following protocol: 10 mL of fluorescein was injected into the renal cavities and left indwelling for 5 minutes. A 3Frdiameter probe (UroFlex Ô B) was inserted through the working channel of the ureteroscope and then placed in contact with the lesions. The reading of the surgeon (low grade vs high grade) was documented in the operation report. Biopsies using a 3 Fr biopsy forceps or a 1.8 Nitinol Basket (COOK) were then performed. The same dedicated genitourinary pathologist blind to the surgeon reading, examined all specimens. A third person compared the informations obtained with CLE with the corresponding histopathological reports.
RESULTS: Data on 15 patients (13 males and 2 females) are reported. The mean age was 70 (range 61-81). Mean diameter of tumors at CT scan was 22 mm (range 8-50 mm). Tumor locations were: two in the renal calyxes, three in the renal pelvis, 4 in the proximal ureter and 6 in the distal ureter. A total of 22 biopsies were taken. In 9 patients CLE allowed to obtain images with characteristic features compatible with low-grade (LG) UTUC; in 5 patients with high grade (HG) UTUC and in one case CIS. We found correspondence between the CLE images and the final histopathological results in 7/9 cases of LG UTUC (78%), in 4/5 cases of HG UTUC (80%) and in 1/1 case of CIS (100%). In the LG UTUC group two cases (22%) were up-staged to HG at the final histopathology. In the HG UTUC one case (20%) was down-staged to LG.
CONCLUSIONS: CLE might improve the accuracy of the available current tools to characterize the grade of UTUC, therefore providing a better selection of patients for a conservative endourological treatment. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1039
Source of Funding: none

